Ozempic, Wegovy, Mounjaro, Zepbound Associated With Loss of Eyesight
(Posted by Tom Lamb at Drug Injury Watch)
Non-arteritic anterior ischemic optic neuropathy (NAION) is a GLP-1 side effect that harms vision by causing damage to the eyes. In the
Drug Injury Watch
Drug Injury Watch, published by the Law Offices of Thomas J. Lamb, P.A., focuses on legal and medical information related to adverse effects and injuries caused by prescription drugs. The blog covers topics such as drug recalls, side effects, and emerging drug injury lawsuits involving medications like Andexxa, Wegovy, Ozempic, Dupixent, and Depo-Provera. It provides updates on medical studies linking drugs to specific injuries, FDA actions, and legal claims for compensation. The site emphasizes individual drug injury cases rather than class actions, offering free case evaluations and insights from attorney Tom Lamb based on extensive experience in drug injury litigation.
Blog Authors
Latest from Drug Injury Watch
Tavneos Liver Risks Confirmed by Medical Registry Data in the US
By Tom Lamb
Possible Legal Compensation Cases for People Who Developed Tavneos Liver Injury
(Posted by Tom Lamb at Drug Injury Watch)
We had been reporting on Tavneos liver risks earlier this year, as seen below:
GLP-1 Lawsuits Involving NAION Filed in Federal Court: 200 Cases as of August 2026
By Tom Lamb
Patients Using Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound Seek Legal Compensation for Vision Loss
(Posted by Tom Lamb at Drug Injury Watch)
In December 2025, GLP-1 lawsuits involving NAION filed in federal court were consolidated by the U.S. Judicial…
Ozempic Eye Problems Side Effect Warnings Not In US Drug Label
By Tom Lamb
Ozempic NAION Risk Is Highlighted In Other Countries, So Why Not Here?
(Posted by Tom Lamb at Drug Injury Watch)
The current Prescribing Information document for Ozempic (Revised: 5/2026 version) in the US does not include any warnings about…
Semaglutide-associated Vision Loss Due to NAION – New Medical Report, May 2026
By Tom Lamb
Ozempic, Wegovy, and Rybelsus Are Semaglutide Drugs Linked to Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
(Posted by Tom Lamb at Drug Injury Watch)
Before we direct you to a new medical report about semaglutide-associated vision loss due to NAION,…
Ozempic And Other GLP-1RA Use Associated With NAION Eye Side Effect
By Tom Lamb
New 2026 Medical Article Published By JAMA Network Open Investigates Drug Safety Issue
(Posted by Tom Lamb at Drug Injury Watch)
An increasingly known but still-developing drug safety issue is that of Ozempic and other GLP-1RA use associated with…
Tavneos Warnings For VBDS Liver Side Effect Increased In April 2026
By Tom Lamb
Tavneos Drug Label Change By Amgen Just 2 Days After Tavneos Drug Recall Statement By FDA
(Posted by Tom Lamb at Drug Injury Watch)
The Tavneos drug safety issue has an interesting new development. On April 29, 2026, Amgen…
Tavneos Lawsuits for Drug Injury After Possible Tavneos Recall
By Tom Lamb
Cases Include Tavneos Drug-Induced Liver Injury (DILI), Tavneos Deaths, Liver Side Effects
(Posted by Tom Lamb at Drug Injury Watch)
Observers in the drug injury and pharmaceutical safety sectors have been watching for a possible Tavneos recall since the…
Tavneos Liver Injury Drug Safety Communication Issued by FDA in Late March 2026
By Tom Lamb
Just 2 Months Earlier, Amgen Refused an FDA Request to Withdraw Tavneos; Will There Be a Tavneos Recall Soon?
(Posted by Tom Lamb at Drug Injury Watch)
On March 31, 2026, the FDA issued a Tavneos liver injury Drug…
Wegovy and Ozempic Vision Loss: Wegovy Rate 5x Higher vs. Ozempic, Men 3x More Often vs. Women
By Tom Lamb
Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Semaglutide Study 2026 Data Analysis
(Posted by Tom Lamb at Drug Injury Watch)
A March 2026 British Journal of Ophthalmology medical journal article, “Ischemic optic neuropathy with semaglutide: global observational analysis of…